Spinal Nerve Root Decompression Post-Op [1818]

General	
Common Present on Admission Diagnosis	
[] Acidosis	Post-op
[] Acute Post-Hemorrhagic Anemia	Post-op
[] Acute Renal Failure	Post-op
[] Acute Respiratory Failure	Post-op
[] Acute Thromboembolism of Deep Veins of Lower	Post-op
Extremities	1 00t 0p
[] Anemia	Post-op
[1] Bacteremia	Post-op
Bipolar disorder, unspecified	Post-op
[] Cardiac Arrest	Post-op
[] Cardiac Dysrhythmia	Post-op
[] Cardiogenic Shock	Post-op
[] Decubitus Ulcer	Post-op
Dementia in Conditions Classified Elsewhere	Post-op
Disorder of Liver	Post-op
[] Electrolyte and Fluid Disorder	Post-op
	Post-op
 Intestinal Infection due to Clostridium Difficile Methicillin Resistant Staphylococcus Aureus Infection 	Post-op
	Post-op
	·
<u> </u>	Post-op
Other and Unspecified Coagulation Defects	Post-op
Other Pulmonary Embolism and Infarction	Post-op
[] Phlebitis and Thrombophlebitis	Post-op
Protein-calorie Malnutrition	Post-op
[] Psychosis, unspecified psychosis type	Post-op
[] Schizophrenia Disorder	Post-op
[] Sepsis	Post-op
[] Septic Shock	Post-op
[] Septicemia	Post-op
[] Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled	Post-op
[] Urinary Tract Infection, Site Not Specified	Post-op
Elective Outpatient, Observation, or Admission (Single	Response)
() Elective outpatient procedure: Discharge following	Routine, Continuous, PACU & Post-op
routine recovery	Noutine, Continuous, 1 700 & 1 0st-op
() Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
	Patient Condition:
	Bed request comments:
	PACU & Post-op
() Outpatient in a bed - extended recovery	Diagnosis:
	Admitting Physician:
	Bed request comments:
	PACU & Post-op
() Admit to Inpatient	Diagnosis:
	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights. PACU & Post-op
Printed on 9/17/2020 at 8:35 AM from SUP	·
CONTROL ON 9/17/20/0 AL - 8:35 AIVENOM SUP	Page 1 of 2

Admission or Observation (Single Response) Patient has active outpatient status order on file

() Admit to Inpatient	Diagnosis: Admitting Physician: Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights. PACU & Post-op
) Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician: Patient Condition:
	Bed request comments:
	PACU & Post-op
) Outpatient in a bed - extended recovery	Diagnosis:
	Admitting Physician:
	Bed request comments:
Y T	PACU & Post-op
) Transfer patient	Level of Care:
	Bed request comments:
) Return to previous bed	Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT
() Return to previous bed	Noutine, onthi discontinued, Starting 3, Scheddling/AD1
Admission (Single Response) Patient has active status order on file	
() Admit to inpatient	Diagnosis:
	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments: Certification: I certify that based on my best clinical judgmen
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more mignights.
	services for two or more midnights. PACU & Post-op
) Transfer patient	
) Transfer patient	PACU & Post-op
·	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT
	PACU & Post-op Level of Care: Bed request comments:
() Return to previous bed	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT
) Return to previous bed	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT
() Return to previous bed Transfer (Single Response) Patient has active inpatient status order on file	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT
() Return to previous bed Fransfer (Single Response) Patient has active inpatient status order on file	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT
() Return to previous bed Fransfer (Single Response) Patient has active inpatient status order on file	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Level of Care:
() Return to previous bed Transfer (Single Response) Patient has active inpatient status order on file () Transfer patient	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Level of Care: Bed request comments:
() Return to previous bed Transfer (Single Response) Patient has active inpatient status order on file () Transfer patient	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Level of Care: Bed request comments: Scheduling/ADT
() Return to previous bed Transfer (Single Response) Patient has active inpatient status order on file () Transfer patient () Return to previous bed	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Level of Care: Bed request comments: Scheduling/ADT
() Return to previous bed Transfer (Single Response) Patient has active inpatient status order on file () Transfer patient () Return to previous bed Code Status [] Full code	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT
() Return to previous bed Fransfer (Single Response) Patient has active inpatient status order on file () Transfer patient () Return to previous bed Code Status [] Full code [] DNR (Do Not Resuscitate) (Selection Required)	PACU & Post-op Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Level of Care: Bed request comments: Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Routine, Until discontinued, Starting S, Scheduling/ADT Code Status decision reached by:

[] Consult to Palliative Care Service	Priority: Reason for Consult? Order?
	Name of referring provider: Enter call back number:
[] Consult to Social Work	Reason for Consult: Post-op
[] Modified Code	Does patient have decision-making capacity? Modified Code restrictions: Post-op
[] Treatment Restrictions	Treatment Restriction decision reached by: Specify Treatment Restrictions: Post-op
Isolation	
Airborne isolation status	
[] Airborne isolation status	Details
[] Mycobacterium tuberculosis by PCR - If you suspect Tuberculosis, please order this test for rapid diagnostics.	Once, Sputum, Post-op
[] Contact isolation status	Details
Droplet isolation status	Details
[] Enteric isolation status	Details
Precautions	
Aspiration precautions	PACU & Post-op
[X] Fall precautions	Increased observation level needed:
	PACU & Post-op
[] Latex precautions	PACU & Post-op
[] Seizure precautions	Increased observation level needed:
[] Spinal precautions	PACU & Post-op PACU & Post-op
Nursing	
Vital Signs (Single Response)	
(X) Vital signs - T/P/R/BP	Routine, Every hour
(X) Vital Signs - 1/1 /1VDI	Until stable, then every 2 hours until A.M., then routine, PACU & Post-op
Activity (Selection Required)	
[] Out of bed with assistance	Routine, Until discontinued, Starting S Specify: Out of bed,Up with assistance Walk in hallways 1-2 times as soon as patient is able, PACU
	Post-op
Strict bed rest	Routine, Until discontinued, Starting S, PACU & Post-op
[] Up ad lib	Routine, Until discontinued, Starting S
	Specify: Up ad lib PACU & Post-op
[] All meals out of bed	Routine, Until discontinued, Starting S, PACU & Post-op
[] Elevate Head of bed 30 degrees	Routine, Until discontinued, Starting S Head of bed: 30 degrees PACU & Post-op
[] Head of bed flat	Routine, Until discontinued, Starting S Head of bed: flat PACU & Post-op
Nursing	
Straight Cath Once and Notify	

[] Straight cath	Routine, Conditional Frequency If patient unable to void, straight cath once and notify physician., PACU & Post-op
[] Notify Physician if Straight Cath	Routine, Until discontinued, Starting S, PACU & Post-op
[] Straight cath	Routine, Every 6 hours If unable to void after second attempt, insert Foley and call physician., PACU & Post-op
[] Insert/Maintain Foley and Notify	
[] Insert Foley catheter	Routine, Once Type: Size: Urinometer needed: If unable to void after second attempt at straight cath, insert Foley and caphysician, PACU & Post-op
[] Foley catheter care	Routine, Until discontinued, Starting S Orders: Maintain to gravity/bedside drain, PACU & Post-op
[] Notify Physician if unable to void after second attempt at straight cath and Foley inserted	Routine, Until discontinued, Starting S, PACU & Post-op
[] Surgical/incision site care	Routine, Once Location: Site: Apply: Dressing Type: Open to air? PACU & Post-op
[X] Reinforce dressing	Routine, As needed Reinforce with: If saturated and call physician., PACU & Post-op
[] Soft cervical collar	Routine, Once Type of Collar to Apply: Soft Collar Special Instructions: Obtain from central supply PACU & Post-op
[] Philadelphia collar	Routine, Once Type of Collar to Apply: Philadelphia Collar Special Instructions: Obtain from central supply PACU & Post-op
[] Miami J collar	Routine, Once Type of Collar to Apply: Miami J Collar Special Instructions: Obtain from orthotic provider. PACU & Post-op
[] Call Raborn Orthotics at 713-349-8117 for appli orthotic device	
[] Drain care	Routine, Until discontinued, Starting S Drain 1: Drain 2: Drain 3: Drain 4: All Drains: PACU & Post-op
[] Place antiembolic stockings - Bilateral thigh high	
[] No anticoagulants INcluding UNfractionated hep	
[] No anti-platelet agents INcluding aspirin	Routine, Until discontinued, Starting S Reason for "No" order: PACU & Post-op
Notify	
[X] Notify Physician if acute change in neurological[X] Notify Physician bleeding at site	Routine, Until discontinued, Starting S, PACU & Post-op Routine, Until discontinued, Starting S, PACU & Post-op

[X] Notify Physician of No Bowel Movement for more than 72 hours	Routine, Until discontinued, Starting S, PACU & Post-op
Diet	
[] Diet - Clear liquids (advance as tolerated to Regular)	Diet effective now, Starting S Diet(s): Clear Liquids Advance Diet as Tolerated? Yes
	Target Diet: Regular Advance target diet criteria: Please assess bowel sounds
	between progressions. Liquid Consistency:
	Fluid Restriction: Foods to Avoid: When awake; advance as tolerated, PACU & Post-op
] Diet - Regular	Diet effective now, Starting S Diet(s): Regular
	Advance Diet as Tolerated? Liquid Consistency:
	Fluid Restriction: Foods to Avoid:
	PACU & Post-op
[] Diet - Heart healthy	Diet effective now, Starting S Diet(s): Heart Healthy Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction: Foods to Avoid:
] Diet - 2000 Kcal/225 gm Carb	PACU & Post-op Diet effective now, Starting S
	Diet(s): 2000 Kcal/225 gm Carbohydrate Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction: Foods to Avoid:
I Diet	PACU & Post-op
[] Diet	Diet effective now, Starting S Diet(s):
	Other Options: Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction: Foods to Avoid:
	PACU & Post-op
Education	
Datient education - Activity	Routine, Once Patient/Family:
	Education for: Activity
20 D. C. A. L. C. C. D. L. L. C.	PACU & Post-op
[X] Patient education - Deep breathing and coughing exercises	Routine, Once Patient/Family:
	Education for: Other (specify) Specify: Deep breathing and coughing exercises
	PACU & Post-op
[X] Patient education - Incentive spirometry	Routine, Once Patient/Family:
	Education for: Incentive spirometry PACU & Post-op
[X] Patient education - Pain management	Routine, Once Patient/Family:
	Education for: Other (specify)
	Specify: Pain management PACU & Post-op
Printed on 9/17/2020 at 8:35 AM from SUP	Page 5

Patient education - Smoking cessation	Routine, Once
	Patient/Family:
	Education for: Smoking cessation counseling PACU & Post-op
[X] Patient education - Wound care	Routine, Once
[-1 - and -	Patient/Family:
	Education for: Other (specify)
	Specify: Wound care
	PACU & Post-op
IV Fluids	
IV Fluids (Single Response)	
() lactated Ringer's infusion	intravenous, continuous, Post-op
() sodium chloride 0.9 % infusion	intravenous, continuous, Post-op
() sodium chloride 0.9 % with potassium chloride 20 infusion	0 mEq/L intravenous, continuous, Post-op
() dextrose 5 % and sodium chloride 0.45 % with potassium chloride 20 mEq/L infusion - for NPO I	intravenous, continuous, Post-op Patients
Medications	
Steroids (Single Response)	
() dexamethasone (DECADRON) IV	4 mg, intravenous, every 6 hours scheduled, Post-op
() methylPREDNISolone sodium succinate (Solu-MEDROL) injection	40 mg, intravenous, every 6 hours scheduled, Post-op
() methylPREDNISolone (MEDROL PAK) dose pactin AM)	ck (start
THIS A PANEL. DO NOT EDIT.	
[] methylPREDNISolone (MEDROL) tablet	8 mg, oral, before breakfast - one time, For 1 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, after lunch - one time, S at 12:00 PM, For 1 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, after dinner - one time, For 1 Doses, Post-op All day-1 doses may be given (up to 6 tablets) may be given at one time based on time of day.
[] methylPREDNISolone (MEDROL) tablet	8 mg, oral, nightly - one time, For 1 Doses, Post-op
	All day-1 doses may be given (up to 6 tablets) may be given at one time based on time of day.
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, 3 times daily around food, Starting S+1, For 3 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	8 mg, oral, nightly - one time, Starting S+1, For 1 Doses, Post-op
[] methylPREDNISolone (MEDROL) tablet	4 mg, oral, 4 times daily tapering, Starting S+2, Post-op
Medications	WOULD IN THE STATE OF THE STATE
[] pantoprazole (PROTONIX) IV or ORAL	"Or" Linked Panel 40 mg, oral, daily at 0600, Post-op
[] pantoprazole (PROTONIX) EC tablet	Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
[] pantoprazole (PROTONIX) 40 mg in sodium	40 mg, intravenous, daily at 0600, Post-op
chloride 0.9 % 10 mL injection	Indication(s) for Proton Pump Inhibitor (PPI) Therapy:
Medications - Bowel Management	
[] polyethylene glycol (MIRALAX) packet	17 g, oral, 2 times daily, Post-op
[] Stool Softener Options (Single Response)	
() docusate sodium (COLACE) capsule	100 mg, oral, 2 times daily, Post-op
() sennosides-docusate sodium (SENOKOT-S) 8.6-50 mg per tablet	2 tablet, oral, nightly, Post-op
Antibiotics - NOT HMWB (Single Response)	
() Antibiotics - Neurosurgery - patients with surgical	l site
drains	

[]	cefazolin (ANCEF) IV - until drains removed	1 g, intravenous, every 8 hours, Post-op
		Administer until all drains removed.
		Type of Therapy: New Anti-Infective Order
-	coforing (MANIDIME) IV until ducing	Reason for Therapy: Surgical Prophylaxis
[]		1 g, intravenous, every 12 hours, Post-op Administer until all drains removed.
	removed	Type of Therapy: New Anti-Infective Order
		Reason for Therapy: Surgical Prophylaxis
[]	vancomycin (VANCOCIN) - until drains	1 g, intravenous, every 12 hours, Post-op
"	removed	Administer until all drains removed.
	Tomovou	Type of Therapy: New Anti-Infective Order
		Reason for Therapy: Surgical Prophylaxis
		Indication:
	Antibiotics - Neurosurgery - patients withOUT sur site drains	gical
[]	cefazolin (ANCEF) IV	1 g, intravenous, once, Starting H, For 1 Doses, Post-op
	,	Type of Therapy: New Anti-Infective Order
		Reason for Therapy: Surgical Prophylaxis
[]	cefepime (MAXIPIME) IV	1 g, intravenous, once, Starting H, For 1 Doses, Post-op
	,	Type of Therapy: New Anti-Infective Order
		Reason for Therapy: Surgical Prophylaxis
[]	vancomycin (VANCOCIN)	1 g, intravenous, once, Starting H, For 1 Doses, Post-op
		Type of Therapy: New Anti-Infective Order
		Reason for Therapy: Surgical Prophylaxis
		Indication:
Anti	emetics	
[X] (ondansetron (ZOFRAN) IV or Oral (Selection Rec	uired) "Or" Linked Panel
[X] ondansetron ODT (ZOFRAN-ODT)	4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op
	disintegrating tablet	Give if patient is able to tolerate oral medication.
[[Y		
[/	() ondansetron (ZOFRAN) 4 mg/2 mL injection	4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
	 ondansetron (ZOFRAN) 4 mg/2 mL injection oromethazine (PHENERGAN) IV or Oral or Recta 	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
		Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
	promethazine (PHENERGAN) IV or Oral or Recta	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel
	promethazine (PHENERGAN) IV or Oral or Recta promethazine (PHENERGAN) 12.5 mg IV	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op
	promethazine (PHENERGAN) IV or Oral or Recta	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op
	promethazine (PHENERGAN) IV or Oral or Recta promethazine (PHENERGAN) 12.5 mg IV	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate
	promethazine (PHENERGAN) IV or Oral or Recta promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication.
	promethazine (PHENERGAN) IV or Oral or Recta promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op
	promethazine (PHENERGAN) IV or Oral or Recta promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to
	promethazine (PHENERGAN) IV or Oral or Recta promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
	promethazine (PHENERGAN) IV or Oral or Recta promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
	promethazine (PHENERGAN) IV or Oral or Recta promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
	promethazine (PHENERGAN) IV or Oral or Rectal promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
[] [] [] [] PRN	promethazine (PHENERGAN) IV or Oral or Rectal promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op
[] [] [] [] PRN	promethazine (PHENERGAN) IV or Oral or Rectal promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater
[]	promethazine (PHENERGAN) IV or Oral or Rectar promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old Medications - Symptom Management accetaminophen (TYLENOL) tablet	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op
[] [] [] []	promethazine (PHENERGAN) IV or Oral or Recta promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old Medications - Symptom Management acetaminophen (TYLENOL) tablet tching - Neurosurgery medications (Single Response)	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op
[]	promethazine (PHENERGAN) IV or Oral or Rectar promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old Medications - Symptom Management accetaminophen (TYLENOL) tablet	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op
[] ; [] ; [] ; [] ; [] ; [] ; [] ; [] ;	promethazine (PHENERGAN) IV or Oral or Rectar promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old I Medications - Symptom Management acetaminophen (TYLENOL) tablet tching - Neurosurgery medications (Single Responsace)	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op onse) ears old when possible.
[]	promethazine (PHENERGAN) IV or Oral or Rectar promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old I Medications - Symptom Management acetaminophen (TYLENOL) tablet tching - Neurosurgery medications (Single Responsacional Symptom Management) cetirizine (ZyrTEC) tablet	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op onse) ears old when possible. 5 mg, oral, daily PRN, itching, Post-op
[] ; [] ; [] ; [] ; [] ; [] ; [] ; [] ;	promethazine (PHENERGAN) IV or Oral or Rectar promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old I Medications - Symptom Management acetaminophen (TYLENOL) tablet tching - Neurosurgery medications (Single Responsace)	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op onse) ears old when possible.
	promethazine (PHENERGAN) IV or Oral or Rectar promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old I Medications - Symptom Management acetaminophen (TYLENOL) tablet tching - Neurosurgery medications (Single Responsacional Symptom Management) cetirizine (ZyrTEC) tablet	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op onse) ears old when possible. 5 mg, oral, daily PRN, itching, Post-op 12.5 mg, intravenous, every 12 hours PRN, itching, Post-op
[]	promethazine (PHENERGAN) IV or Oral or Rectar promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old Medications - Symptom Management acetaminophen (TYLENOL) tablet tching - Neurosurgery medications (Single Responsacional Avoid diphenhydramine use in patients over 70 years of the diphenhydramine (BENADRYL) injection	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op onse) ears old when possible. 5 mg, oral, daily PRN, itching, Post-op 12.5 mg, intravenous, every 12 hours PRN, itching, Post-op
[]	promethazine (PHENERGAN) IV or Oral or Rectar promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old Medications - Symptom Management acetaminophen (TYLENOL) tablet tching - Neurosurgery medications (Single Responsacional Medications (ZyrTEC) tablet cetirizine (ZyrTEC) tablet diphenhydraMINE (BENADRYL) injection Medications - Bowel Management (Single Responsacional Medications - Bowel	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op onse) ears old when possible. 5 mg, oral, daily PRN, itching, Post-op 12.5 mg, intravenous, every 12 hours PRN, itching, Post-op sponse)
[]	promethazine (PHENERGAN) IV or Oral or Rectar promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old Medications - Symptom Management acetaminophen (TYLENOL) tablet tching - Neurosurgery medications (Single Responsational Medications (ZyrTEC) tablet cetirizine (ZyrTEC) tablet diphenhydraMINE (BENADRYL) injection Medications - Bowel Management (Single Responsations) Medications - Bowel Management (Single Responsations)	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op 12.5 mg, oral, daily PRN, itching, Post-op 12.5 mg, intravenous, every 12 hours PRN, itching, Post-op 12.5 mg, intravenous, every 12 hours PRN, itching, Post-op 12.5 mg, oral, daily PRN, constipation, Post-op
[]	promethazine (PHENERGAN) IV or Oral or Rectar promethazine (PHENERGAN) 12.5 mg IV promethazine (PHENERGAN) tablet promethazine (PHENERGAN) suppository scopolamine (TRANSDERM-SCOP) 1.5 mg (1 mg days) - For Patients LESS than 65 years old Medications - Symptom Management acetaminophen (TYLENOL) tablet tching - Neurosurgery medications (Single Responsational Avoid diphenhydramine use in patients over 70 years of the diphenhydramine (BENADRYL) injection Medications - Bowel Management (Single Remagnesium hydroxide suspension bisacodyl (DULCOLAX) EC tablet	Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. "Or" Linked Panel 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication. 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. g over 3 1 patch, transdermal, for 72 Hours, every 72 hours, Post-op 650 mg, oral, every 6 hours PRN, fever, Temperature greater than 101 F, Post-op ars old when possible. 5 mg, oral, daily PRN, itching, Post-op 12.5 mg, intravenous, every 12 hours PRN, itching, Post-op sponse) 30 mL, oral, daily PRN, constipation, Post-op 5 mg, oral, daily PRN, constipation, Post-op

Muscle Relaxants (Single Response)	
() methocarbamol (ROBAXIN) 500 mg in sodium chlo 0.9 % 100 mL IVPB	oride 500 mg, intravenous, for 60 Minutes, every 8 hours PRN, muscle spasms, Post-op
() methocarbamol (ROBAXIN) tablet	500 mg, oral, every 8 hours PRN, muscle spasms, Post-op
() cyclobenzaprine (FLEXERIL) tablet	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op
Muscle Relaxants - Refractory Treatments (Single R	Response)
() diazepam (VALIUM) injection	2.5 mg, intravenous, every 8 hours PRN, muscle spasms, inadequate muscle spasm relief following administration of other agents, Post-op Indication(s): Other Specify: Muscle Relaxant
() diazepam (VALIUM) tablet	2.5 mg, oral, every 8 hours PRN, muscle spasms, inadequate muscle spasm relief following administration of other agents, Post-op Indication(s): Other Specify: Muscle Relaxant
PRN Medications - Pain - Pain Score (1-3) (Single Ro	
() traMADol (ULTRAM) tablet	25 mg, oral, every 4 hours PRN, mild pain (score 1-3), Post-op
	Maximum Daily Dose: 200 mg/day
PCA Medications (Single Response)	
() morPHINE PCA 30 mg/30 mL	
	Loading Dose (optional): Not Ordered PCA Dose: 1 mg Lockou Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.
	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued. - Immediately following PCA administration tubing change, Post-op
	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op

	[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following: naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op 0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
7) h	ydromorPHONE PCA (DILAUDID) 15 mg/30 mL	
	[]	hydromorPHONE (DILAUDID) 15 mg/30 mL PCA	Loading Dose (optional): Not Ordered PCA Dose: 0.2 mg Lockout: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 3 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26662::"0.2"} mg every {Bolus Frequency:26663::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26664::"0.1"} mg ONCE. Adjust doses for age, renal function or other factors. Turn Off PCA Continuous Dose (Basal Rate) On Date:
П			Turn Off PCA Continuous Dose (Basal Rate) At Time:
	[]	Vital signs - T/P/R/BP	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued. - Immediately following PCA administration tubing change, Post-op
	[]	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
	[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
	[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op

[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
()	fentaNYL PCA (SUBLIMAZE) 1500 mcg/30 mL	
	fentaNYL (SÜBLIMAZE) 1500 mcg/30 mL PCA	Loading Dose (optional): Not Ordered PCA Dose: 10 mcg Lockout (recommended 6-8 min): Not Ordered Continuous Dose: 0 mcg/hr MAX (Four hour dose limit): 150 mcg intravenous, continuous, Post-op **Due to fentaNYL 600 mcg/30 mL shortages, the new standard for all facilities will be fentaNYL 1500 mcg/30 mL. This concentration is 2.5 x more concentrated.**
		Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patient 19-59 years old, may bolus {Bolus Dose:26656::"25"} mcg every {Bolus Frequency:26655::"2"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26654::"10"} mcg ONCE. Adjust doses for age, renal function or other factors. Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time:
[Vital signs - T/P/R/BP	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op
	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
[:	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[.	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.

PCA Medications (Single Response)

() m	norPHINE PCA 30 mg/30 mL	
	morPHINE 30 mg/30 mL PCA	Loading Dose (optional): Not Ordered PCA Dose: 1 mg Lockout Interval: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE. Adjust doses for age, renal function or other factors.
	Vital signs - T/P/R/BP	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued. - Immediately following PCA administration tubing change, Post-op
[]	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
() h	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg ydromorPHONE PCA (DILAUDID) 15 mg/30 mL	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
	hydromorPHONE (DILAUDID) 15 mg/30 mL PCA	Loading Dose (optional): Not Ordered PCA Dose: 0.2 mg Lockout: Not Ordered Continuous Dose: 0 mg/hr MAX (Four hour dose limit): 3 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26662::"0.2"} mg every {Bolus Frequency:26663::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26664::"0.1"} mg ONCE. Adjust doses for age, renal function or other factors. Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time:

[]	Vital signs - T/P/R/BP	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued. - Immediately following PCA administration tubing change, Post-op
	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
() f	entaNYL PCA (SUBLIMAZE) 600 mcg/30 mL	
	fentaNYL (SUBLIMAZE) 600 mcg/30 mL PCA	Nurse Loading Dose: Not Ordered PCA Dose: 10 mcg Lockout Interval: Not Ordered Continuous Dose: 0 mcg/hr MAX (Four hour dose limit): 150 mcg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patient 19-59 years old, may bolus {Bolus Dose:26656::"25"} mcg every {Bolus Frequency:26655::"2"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26654::"10"} mcg ONCE. Adjust doses for age, renal function or other factors.
	Vital signs - T/P/R/BP	Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time: Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op

[] Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
[] Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[] Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[] naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg PRN Medications - Pain - Pain Score (4-6) (Single	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
() acetaminophen-codeine (TYLENOL #3) 300-30 itablet	
() traMADol (ULTRAM) tablet	50 mg, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Maximum Daily Dose: 200 mg/day
PRN Medications - Pain - Pain Score (7-10) (Singl	e Response)
() acetaminophen-codeine (TYLENOL #3) 300-30 i tablet	ng per 2 tablet, oral, every 6 hours PRN, severe pain (score 7-10), Post-op Do not exceed 3000 mg of acetaminophen daily from all sources.
Breakthrough Pain (Single Response)	
() fentaNYL (SUBLIMAZE) injection	25 mcg, intravenous, every 2 hour PRN, other, pain (score: 4-10) - inadequate pain relief following administration of oral agents, Post-op Administer after pain re-assessment for inadequate pain relief.
() morphine 2 mg/mL injection	2 mg, intravenous, every 3 hours PRN, other, pain (score: 4-10) - inadequate pain relief following administration of oral agents, Post-op Administer after pain re-assessment for inadequate pain relief.
() HYDROmorphone (DILAUDID) injection	0.5 mg, intravenous, every 3 hours PRN, other, pain (score: 4-10) - inadequate pain relief following administration of oral agents, Post-op Administer after pain re-assessment for inadequate pain relief.

VTE

DVT Risk and Prophylaxis Tool (Single Response) (Selection Required)

URL: "\appt1.pdf"

()	Patient currently has an active order for therapeutic anticoagulant or VTE prophylaxis	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op
()	LOW Risk of DVT (Selection Required)	
	Low Risk Definition Age less than 60 years and NO other VTE risk factor	ors
]] Low Risk (Single Response) (Selection Required	`
	() Low risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation PACU & Post-op
()	MODERATE Risk of DVT - Surgical (Selection Requ	· · · · · · · · · · · · · · · · · · ·
	contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflamma	chanical prophylaxis is optional unless pharmacologic is tion, dehydration, varicose veins, cancer, sepsis, obesity, previous eg swelling, ulcers, venous stasis and nephrotic syndrome
[] Moderate Risk (Selection Required)	
;	[] Moderate risk of VTE	Routine, Once, PACU & Post-op
l	Moderate Risk Pharmacological Prophylaxis - Su Patient (Single Response) (Selection Required)	
	() Contraindications exist for pharmacologic proph BUT order Sequential compression device	
	[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
	[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
	 () Contraindications exist for pharmacologic proph AND mechanical prophylaxis 	ylaxis "And" Linked Panel
	[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
	[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
	() enoxaparin (LOVENOX) injection (Single Responsable (Selection Required)	·
	() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
	() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
	() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min

() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1
		For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS
	weight < 50kg and age > 75yrs)	than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
) M	ODERATE Risk of DVT - Non-Surgical (Selection	on

() MODERATE Risk of DVT - Non-Surgical (Selection Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

[] Moderate Risk (Selection Required)	
[] Moderate risk of VTE	Routine, Once, PACU & Post-op
Moderate Risk Pharmacological Prophylaxis -	4i a m
Non-Surgical Patient (Single Response) (Selec Required)	uion
() Contraindications exist for pharmacologic prop Order Sequential compression device	phylaxis - "And" Linked Panel
[] Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
FI DI MALLE	PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
() Contraindications exist for pharmacologic propagation AND mechanical prophylaxis	phylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
	PACU & Post-op
[] Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following
	contraindication(s):
	PACU & Post-op

(Selection Required) () enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, PACU & Post-op
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, PACU & Post-op Indication:
	marodion.

() HIGH Risk of DVT - Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High Risk (Selection Required)	
	Douting Once DACIL® Doct on
[] High risk of VTE	Routine, Once, PACU & Post-op
[] High Risk Pharmacological Prophylaxis - Surg (Single Response) (Selection Required)	ical Patient
() Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
,	contraindication(s):
	PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	sponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1
· · ·	For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min

() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.
	This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g.	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op
weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
(COUMADIN)	Indication:
Mechanical Prophylaxis (Single Response) (Sometime Required)	election
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
HIGH Risk of DVT - Non-Surgical (Selection Req	uired)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
[] High Risk Pharmacological Prophylaxis - Non-S Patient (Single Response) (Selection Required)	
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min

	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
$\overline{()}$	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700 Indication:
()	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[]	Mechanical Prophylaxis (Single Response) (Sel Required)	lection
()	Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
()	Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
	GH Risk of DVT - Surgical (Hip/Knee) (Selection equired)	ו
Bo O Th or So A M Al Ao	gh Risk Definition oth pharmacologic AND mechanical prophylaxis ne or more of the following medical conditions: nrombophilia (Factor V Leiden, prothrombin varia protein S deficiency; hyperhomocysteinemia; m evere fracture of hip, pelvis or leg acute spinal cord injury with paresis ultiple major traumas odominal or pelvic surgery for CANCER cute ischemic stroke story of PE	ant mutations, anticardiolipin antibody syndrome; antithrombin, protein C

[] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
[] High Risk Pharmacological Prophylaxis - Hip o	
(Arthroplasty) Surgical Patient (Single Respons	se)
(Selection Required)	
() Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1
	Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Res	sponse)
(Selection Required)	40
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() enoxaparin (LOVENOX) syringe	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1
() enoxaparin (LOVENOX) syringe - For	30 mg, subcutaneous, daily at 0600, Starting S+1
Patients with CrCL LESS than 30 mL/min	For Patients with CrCL LESS than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1
CrCl GREATER than 30 mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.

•	enoxaparin (LOVENOX) syringe - For Patients weight between 140 kg or	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1
	GREATER and CrCl GREATER than 30 mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1
()	, ,	If the patient does not have a history or suspected case of
		Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication
		Contraindicated in patients LESS than 50kg, prior to surgery/invasive
		procedure, or CrCl LESS than 30 mL/min
		This patient has a history of or suspected case of Heparin-Induced
		Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
	heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM
()	for patients with high risk of bleeding, e.g.	Recommended for patients with high risk of bleeding, e.g. weight LESS
	weight < 50kg and age > 75yrs)	
		than 50kg and age GREATER than 75yrs.
()	rivaroxaban (XARELTO) tablet for hip or	10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1
	knee arthroplasty planned during this	To be Given on Post Op Day 1.
	admission	Indications:
()	warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1
		Indication:
()	Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
	(COUMADIN)	Indication:
	Mechanical Prophylaxis (Single Response) (Se Required)	lection
()	Contraindications exist for mechanical	Routine, Once
	prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s) PACU & Post-op
	DI /NA ' / '	D " O " DAOLLOD '
()	Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
.,	device continuous	
.,		
.,	device continuous	
DVT Ri	device continuous isk and Prophylaxis Tool (Single Response)	URL: "\appt1.pdf"
DVT Ri	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti	URL: "\appt1.pdf"
DVT Ri	device continuous isk and Prophylaxis Tool (Single Response)	URL: "\appt1.pdf" c Routine, Once No pharmacologic VTE prophylaxis because: patient is
DVT Ri	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti	URL: "\appt1.pdf" Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.
OVT Ri	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti	URL: "\appt1.pdf" Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
OVT Ri) Pat anti	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti icoagulant or VTE prophylaxis	URL: "\appt1.pdf" Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.
OVT Ri	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti icoagulant or VTE prophylaxis W Risk of DVT (Selection Required)	URL: "\appt1.pdf" Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
DVT Ri () Pat anti	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti icoagulant or VTE prophylaxis W Risk of DVT (Selection Required) w Risk Definition	URL: "\appt1.pdf" Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op
DVT Ri () Pat anti	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti icoagulant or VTE prophylaxis W Risk of DVT (Selection Required)	URL: "\appt1.pdf" Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op
OVT Ri	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti icoagulant or VTE prophylaxis W Risk of DVT (Selection Required) W Risk Definition e less than 60 years and NO other VTE risk fac	URL: "\appt1.pdf" C Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op
DVT Ri () Pat anti () LO' Lov Age	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti icoagulant or VTE prophylaxis W Risk of DVT (Selection Required) w Risk Definition e less than 60 years and NO other VTE risk factors Low Risk (Single Response) (Selection Required)	URL: "\appt1.pdf" C Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op tors
DVT Ri () Pat anti () LO' Lov Age	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti icoagulant or VTE prophylaxis W Risk of DVT (Selection Required) W Risk Definition e less than 60 years and NO other VTE risk fac	URL: "\appt1.pdf" C Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op tors ed) Routine, Once
DVT Ri () Pat anti () LO' Lov Age	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti icoagulant or VTE prophylaxis W Risk of DVT (Selection Required) w Risk Definition e less than 60 years and NO other VTE risk factors Low Risk (Single Response) (Selection Required)	URL: "\appt1.pdf" C Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op tors ed) Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae
DVT Ri () Pat anti () LO' Lov Age	device continuous isk and Prophylaxis Tool (Single Response) tient currently has an active order for therapeuti icoagulant or VTE prophylaxis W Risk of DVT (Selection Required) w Risk Definition e less than 60 years and NO other VTE risk factors Low Risk (Single Response) (Selection Required)	URL: "\appt1.pdf" C Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op tors ed) Routine, Once

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

Moderate Risk (Selection Required) Moderate risk of VTE	Routine, Once, PACU & Post-op
] Moderate Risk Pharmacological Prophylaxis - Patient (Single Response) (Selection Required	
() Contraindications exist for pharmacologic pro BUT order Sequential compression device	
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
() Contraindications exist for pharmacologic pro	ophylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Re- (Selection Required)	sponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU 8 Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS
red on 9/17/2020 at 8:35 AM from SLIP	than 50kg and age GREATER than 75yrs.

() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
() MODERATE Risk of DVT - Non-Surgical (Selection	ction

Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

Moderate risk of VTE	Routine, Once, PACU & Post-op
Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Selec Required)	tion
() Contraindications exist for pharmacologic prop Order Sequential compression device	ohylaxis - "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
 Contraindications exist for pharmacologic prop AND mechanical prophylaxis 	ohylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 3 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 3 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this

()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, PACU & Post-op
()	heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours, PACU & Post-op
	for patients with high risk of bleeding, e.g.	Recommended for patients with high risk of bleeding, e.g. weight LESS
	weight < 50kg and age > 75yrs)	than 50kg and age GREATER than 75yrs.
()	warfarin (COUMADIN) tablet	oral, daily at 1700, PACU & Post-op
	,	Indication:
()	Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
,	(COUMADIN)	Indication:

() HIGH Risk of DVT - Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
 High Risk Pharmacological Prophylaxis - Surgi (Single Response) (Selection Required) 	cal Patient
() Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
() (OVENOV):: (: (O: L.B.	PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Res (Selection Required)	sponse)
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1
CrCl GREATER than 30 mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30
() () () () () () () () () () () () () (mL/min
() patients weight 140 kg or GREATER AND	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1
CrCl GREATER than 30 mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op
() Totalparmax (a to tri a t) injection	If the patient does not have a history or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive
	procedure, or CrCl LESS than 30 mL/min.
	This patient has a history of or suspected case of Heparin-Induced
() () () () ()	Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
() heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU &
for patients with high risk of bleeding, e.g.	Post-op
weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:

^[] Mechanical Prophylaxis (Single Response) (Selection Required)

() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() Place/Maintain sequential compression	Routine, Continuous, PACU & Post-op
device continuous	

() HIGH Risk of DVT - Non-Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High risk of VTE	Routine, Once, PACU & Post-op
 High Risk Pharmacological Prophylaxis - Non-Su Patient (Single Response) (Selection Required) 	irgical
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Responsable (Selection Required)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 3 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
Mechanical Prophylaxis (Single Response) (Sele Required)	ction
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s PACU & Post-op
() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op

Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

[] High Risk (Selection Required) [] High risk of VTE [] High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) (Selection Required) () Contraindications exist for pharmacologic prophylaxis () apixaban (ELIQUIS) tablet () apixaban (ELIQUIS) tablet () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 100-139 kg	
High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) (Selection Required) () Contraindications exist for pharmacologic prophylaxis () apixaban (ELIQUIS) tablet () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 10	
(Arthroplasty) Surgical Patient (Single Response) (Selection Required) () Contraindications exist for pharmacologic prophylaxis and the following contraindication (s): () apixaban (ELIQUIS) tablet Seponse (selection Required) () aspirin chewable tablet Selection Required) () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe Selection Required Response) (Selection Required) () enoxaparin (LOVENOX) syringe Selection Required Response) (Selection Required) () enoxaparin (LOVENOX) syringe Selection Required Response) (Selection Required) () enoxaparin (LOVENOX) syringe Selection Required Response) (Selection Required) () enoxaparin (LOVENOX) syringe Selection Response) (Selection Required) () enoxapari	
() Contraindications exist for pharmacologic prophylaxis Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): () apixaban (ELIQUIS) tablet 2.5 mg, oral, every 12 hours, Starting S+1 Indications: () aspirin chewable tablet 162 mg, oral, daily, Starting S+1 () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min CrCl GREATER than 30 mL/min For Patients weight between 100-139 kg and CrCl GREATER than 100-139 kg and Cr	
prophylaxis No pharmacologic VTE prophylaxis due to the following contraindication(s): () apixaban (ELIQUIS) tablet 2.5 mg, oral, every 12 hours, Starting S+1 Indications: () aspirin chewable tablet 162 mg, oral, daily, Starting S+1 () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.	
contraindication(s): () apixaban (ELIQUIS) tablet 2.5 mg, oral, every 12 hours, Starting S+1 Indications: () aspirin chewable tablet 162 mg, oral, daily, Starting S+1 () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.	
() apixaban (ELIQUIS) tablet 2.5 mg, oral, every 12 hours, Starting S+1 Indications: () aspirin chewable tablet 162 mg, oral, daily, Starting S+1 () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.	
Indications: () aspirin chewable tablet 162 mg, oral, daily, Starting S+1 () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	
() aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	
 () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe	
() enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min (Selection Required) 40 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.	
() enoxaparin (LOVENOX) syringe () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min 30 mg, subcutaneous, 2 times daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 100-	
Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min Starting S+1 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 100-139 kg and CrC	
Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1) For Patients with CrCL LESS than 30 mL/min.	CAL),
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 100-139 kg and CrCl G	
Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than mL/min.	
CrCl GREATER than 30 mL/min For Patients weight between 100-139 kg and CrCl GREATER th mL/min.	CAL),
mL/min.	
() enoxaparin (LOVENOX) syringe - For 40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITIC	
	CAL),
Patients weight between 140 kg or Starting S+1	
GREATER and CrCl GREATER than 30 For Patients weight 140 kg or GREATER and CrCl GREATER th	1an 30
mL/min mL/min	
() fondaparinux (ARIXTRA) injection 2.5 mg, subcutaneous, daily, Starting S+1	
If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this med	lication
Contraindicated in patients LESS than 50kg, prior to surgery/inva	
procedure, or CrCl LESS than 30 mL/min	SIVC
This patient has a history of or suspected case of Heparin-Induce	d
Thrombocytopenia (HIT):	
() heparin (porcine) injection 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM	
() heparin (porcine) injection (Recommended 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM	
for patients with high risk of bleeding, e.g. Recommended for patients with high risk of bleeding, e.g. weight	LESS
weight < 50kg and age > 75yrs) than 50kg and age GREATER than 75yrs.	
() rivaroxaban (XARELTO) tablet for hip or 10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1	
knee arthroplasty planned during this To be Given on Post Op Day 1.	
admission Indications:	
() warfarin (COUMADIN) tablet oral, daily at 1700, Starting S+1 Indication:	
() Pharmacy consult to manage warfarin STAT, Until discontinued, Starting S Indication:	

Required)

Mechanical Prophylaxis (Single Response) (Selection

() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
Labs	
Labs	
	Once, PACU & Post-op
[] Hemoglobin and hematocrit	Office, FACO & Fost-op
Labs - AM	
[] Basic metabolic panel	AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op
[] CBC with platelet and differential	AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op
[X] Partial thromboplastin time	AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op
[] Prothrombin time with INR	AM draw, Starting S+1 For 1 Occurrences, PACU & Post-op
Labs - AM Daily x 3	
[] Hemoglobin	AM draw repeats For 3 Occurrences, PACU & Post-op
Imaging	
СТ	
[] CT Cervical Spine Wo Contrast	Routine, 1 time imaging For 1 , PACU & Post-op
[] CT Thoracic Spine Wo Contrast	Routine, 1 time imaging For 1 , PACU & Post-op
[] CT Lumbar Spine Wo Contrast	Routine, 1 time imaging For 1 , PACU & Post-op
X-ray	
[] Chest 1 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] Chest 1 Vw in AM	Routine, 1 time imaging, Starting S+1 For 1 , PACU & Post-op
[] Chest 2 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] XR Spine Scoliosos 2-3 Views	Routine, 1 time imaging For 1 Please add 32 millimeter image calibration necklace to the field of view., PACU & Post-op
[] Thoracic Spine 1 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] Lumbar Spine 1 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] Lumbar Spine Ap Lateral Flexion And Extension	Routine, 1 time imaging For 1 , PACU & Post-op
[] Lumbar Spine Complete 4+ Vw	Routine, 1 time imaging For 1 , PACU & Post-op
[] Thoracolumbar Spine 2 Vw	Routine, 1 time imaging For 1 , PACU & Post-op
Consults	
For Physician Consult orders use sidebar	
Ancillary Consults	
[] Consult to Case Management	Consult Reason: PACU & Post-op
[] Consult to Social Work	Reason for Consult:
	PACU & Post-op
[] Consult to PT eval and treat	Reasons for referral to Physical Therapy (mark all applicable):
	Are there any restrictions for positioning or mobility?
	Please provide safe ranges for HR, BP, O2 saturation(if values are very abnormal):
	Weight Bearing Status:
	PACU & Post-op
[] Consult PT wound care	Special Instructions:
	Location of Wound?
	PACU & Post-op

Consult to OT eval and treat	Reason for referral to Occupational Therapy (mark all that apply):
	Are there any restrictions for positioning or mobility?
	Please provide safe ranges for HR, BP, O2 saturation(if
	values are very abnormal):
	Weight Bearing Status:
	PACU & Post-op
Consult to Nutrition Services	Reason For Consult?
••	Purpose/Topic:
	PACU & Post-op
Consult to Spiritual Care	Reason for consult?
'	PACU & Post-op
[] Consult to Speech Language Pathology	Routine, Once
	Reason for consult:
	PACU & Post-op
[] Consult to Wound Ostomy Care nurse	Reason for consult:
	Consult for NPWT:
	Reason for consult:
	PACU & Post-op
Consult to Respiratory Therapy	Reason for Consult?
. , , , , , , , , , , , , , , , , , , ,	PACU & Post-op